Twist Bioscience Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Twist Bioscience Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-4.2×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 56% of Healthcare companies in United States.
Cash Locked Ratio
$19For every $100 of sales, $19 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $27 tied up three years earlier.
Less money tied up than 61% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$81Sales grew 85% in 3 years; of every extra $100 of sales, $81 became extra profit.
Higher than 78% of Healthcare companies in United States.
Asset Productivity Ratio
+85% / -33%In 3 years sales changed by +85% while total assets changed by -33%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-3.4×Operating cash was negative last year, while some debt falls due within a year.
Higher than 61% of Healthcare companies in United States.
Cash Cushion Ratio
+2%Cash, after subtracting all debt, equals 2% of its market value (net cash).
Lower than 64% of Healthcare companies in United States.
Tangible Assets Ratio
85%Of every $100 the company owns, $85 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 56% of Healthcare companies in United States.
Tangible Net Worth Ratio
80%Of every $100 of net worth, $80 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 62% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Twist Bioscience Corporation made a loss over the last year. Twist Bioscience Corporation owes $0.34 for every $1 it owns. Twist Bioscience Corporation made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Sep 2025.
P/E ratio
LossTwist Bioscience Corporation made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
20.81The share price is 20.81 times Twist Bioscience Corporation's book value per share, higher than 94% of Healthcare companies in United States.
Market cap
$9.3 BThe total market value of all of Twist Bioscience Corporation's shares at today's price (share price × number of shares), larger than 89% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$446 MWhat Twist Bioscience Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$6.72Net worth divided by the number of shares. The share price of $139.92 is 20.8 times this, which is the P/B above.
Return on equity (ROE)
-29.6%Twist Bioscience Corporation lost 29.6% of its shareholders' money over the last year, higher than 60% of Healthcare companies in United States.
Owes vs Owns
0.34×Twist Bioscience Corporation owes $0.34 for every $1 it owns (low), lower than 56% of Healthcare companies in United States.
Dividend yield
NoneTwist Bioscience Corporation does not currently pay a dividend.
Revenue growth
+20%Revenue rose 20% in the year to Sep 2025, and grew 23% a year on average over 3 years.
Profit growth
LossTwist Bioscience Corporation made a loss in each of the last two years.
Profit margin
-20.6%Twist Bioscience Corporation lost $21 for every $100 of revenue.
Cash vs debt
Net cashTwist Bioscience Corporation held $157 M more cash than debt (net cash) at Sep 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Twist Bioscience Corporation: $9.3 B ÷ $446 M (30 Jun 2026) = 20.8.
What is Twist Bioscience Corporation's return on equity?
Twist Bioscience Corporation lost 29.6% of its shareholders' money over the last year, higher than 60% of Healthcare companies in United States.
How much does Twist Bioscience Corporation owe compared with what it owns?
Twist Bioscience Corporation owes $0.34 for every $1 it owns (low), lower than 56% of Healthcare companies in United States.
Does Twist Bioscience Corporation pay a dividend?
No. Twist Bioscience Corporation does not currently pay a dividend.
Is Twist Bioscience Corporation's revenue growing?
Revenue rose 20% in the year to Sep 2025, and grew 23% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.